Address: 51368 Leverkusen, Germany
Tel: 49 214 30-1
Web: http://healthcare.bayer.com/scripts/pages/en/index.php
Headquartered in Leverkusen, Bayer HealthCare researches, develops, manufactures and markets innovative products for the prevention, diagnosis and treatment of diseases. The company thus plays an important part in improving the health of people and animals. This subgroup comprises four global divisions: Animal Health, Consumer Care, Medical Care (Diabetes Care and MEDRAD) and Bayer Schering Pharma AG, Germany*. Bayer HealthCare has 53,100 employees worldwide and generated sales of EUR 15,407 million in 2008. The divisions Animal Health and Bayer Schering Pharma AG, Germany* are headquartered in Germany, while Consumer Care and Medical Care (Diabetes Care and MEDRAD) are based in the United States. Bayer HealthCare’s Animal Health and Consumer Care divisions occupy leading positions worldwide.
Worldwide, Bayer is experiencing a strong business momentum thanks to an avalanche of innovation. The general manager of Bayer HealthCare Pharmaceuticals in Mexico shares his perspectives about the recent developments…
The director general of Bayer Maghreb explains how Morocco has real potential to position itself as a hub for the region, talks about the challenges associated with the reforms of…
Bassam Abdallah, Country Division Head of Bayer Healthcare, speaks about the UAE’s economic diversification evolution, how healthcare is the leading segment in this process, and what Bayer’s strategy is to…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
Liam Condon, Managing Director of Bayer Healthcare China discusses the government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It…
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries…
See our Cookie Privacy Policy Here
